• English
    • Persian
    • English
    • Persian
  • English 
    • English
    • Persian
    • English
    • Persian
  • Login
View Item 
  •   KR-TBZMED Home
  • TBZMED Published Academics Works
  • Published Articles
  • View Item
  •   KR-TBZMED Home
  • TBZMED Published Academics Works
  • Published Articles
  • View Item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Evaluation of Propranolol Effect on Experimental Acute and Chronic Toxoplasmosis Using Quantitative PCR.

Thumbnail
Date
2016
Author
Montazeri, M
Ebrahimzadeh, MA
Ahmadpour, E
Sharif, M
Sarvi, S
Daryani, A
Metadata
Show full item record
Abstract
Current therapies against toxoplasmosis are limited, and drugs have significant side effects and low efficacies. We evaluated the potential anti-Toxoplasma activity of propranolol at a dose of 2 or 3 mg/kg of body weight/day in vivo in the acute and chronic phases. Propranolol as a cell membrane-stabilizing agent is a suitable drug for inhibiting the entrance of Toxoplasma gondii tachyzoites into cells. The acute-phase assay was performed using propranolol, pyrimethamine, and propranolol plus pyrimethamine before (pretreatment) and after (posttreatment) intraperitoneal challenge with 1 أ— 103 tachyzoites of the virulent T. gondii strain RH in BALB/c mice. Also, in the chronic phase, treatment was performed 12 h before intraperitoneal challenge with 1 أ— 106 tachyzoites of the virulent strain RH of T. gondii in rats. One week (in the acute phase) and 2 months (in the chronic phase) after postinfection, tissues were isolated and DNA was extracted. Subsequently, parasite load was calculated using quantitative PCR (qPCR). In the acute phase, in both groups, significant anti-Toxoplasma activity was observed using propranolol (P < 0.001). Propranolol in the pretreatment group showed higher anti-Toxoplasma activity than propranolol in posttreatment in brain tissues, displaying therapeutic efficiency on toxoplasmosis. Also, propranolol combined with pyrimethamine reduced the parasite load as well as significantly increased survival of mice in the pretreatment group. In the chronic phase, anti-Toxoplasma activity and decreased parasite load in tissues were observed with propranolol. In conclusion, the presented results demonstrate that propranolol, as an orally available drug, is effective at low doses against acute and latent murine toxoplasmosis, and the efficiency of the drug is increased when it is used in combination therapy with pyrimethamine.
URI
http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/39654
Collections
  • Published Articles

Knowledge repository of Tabriz University of Medical Sciences using DSpace software copyright © 2018  HTMLMAP
Contact Us | Send Feedback
Theme by 
Atmire NV
 

 

Browse

All of KR-TBZMEDCommunities & CollectionsBy Issue DateAuthorsTitlesSubjectsThis CollectionBy Issue DateAuthorsTitlesSubjects

My Account

LoginRegister

Knowledge repository of Tabriz University of Medical Sciences using DSpace software copyright © 2018  HTMLMAP
Contact Us | Send Feedback
Theme by 
Atmire NV